Quinolone use and resistance;Uso de quinolonas y resistencia

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 4, 2004, Pages 201-203

  Oteo, Jesús ^a   Campos, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GENE PRODUCT; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL GENE; BACTERIAL MUTATION; BELGIUM; DRUG UTILIZATION; EDITORIAL; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; ITALY; MINIMUM INHIBITORY CONCENTRATION; PORTUGAL; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 2342511586     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059048     Document Type: Editorial

References (19)

1. Baddour LM, Hicks DV, Tayidi MM, Roberts SK, Walker E, Smith RJ, et al. Risks factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microb Drug Resistant 1995;1:219-22.
2. Goettsch W, Van Pelt W, Nagelkerke N, Hendrix MGR, Buiting AGM, Petit PL, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46:223-8.
3. Cizman M, Orazem M, Krizan-Hergouth V, Kolman J. Correlations between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli urinary tract infection. J Antimicrob Chemother 2001;47:502.
4. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluorquinolones in Canada. N Engl J Med 1999;341:233-9.
5. Ruiz-Bremon A, Ruiz-Tovar M, Pérez-Gorricho B, Díaz de Torres P, López-Rodríguez R. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother 2000;45:395-400.
6. Lázaro E, Madurga M, De Abajo FJ. Evolución del consumo de antibióticos en España, 1985-2000. Med Clin (Barc) 2002;118:561-8.
7. Liñares J, De la Campa AG, Pallarés R. Fluorquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:1546-7.
8. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43:2736-41.
9. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi anf for non-typhi salmonellae. Clin Infect Dis 2003;37:75-81.
10. Butt T, Nadeem Ahmat R, Mahmood A, Zaidi S. Ciprofloxacin treatment failure in typhoid fever case, Pakistan. Emer Infect Dis 2003;9:1621-2.
11. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, De Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
12. Bastida T, Pérez-Vázquez M, Campos J, Corté s-Lletget MC, Román F, Tubau F, et al. Therapeutic failure in a case of pneumonia due to levofloxacin-resistant Haemophilus influenzae. Emerg Infect Dis 2003;9:1475-8.
13. Miró E, Vergés C, García I, Mirelis B, Navarro F, Coll P, et al. Resistencia a betalactámicos y a quinolonas en Salmonella enterica y su relación con mutaciones en las topoisomerasas, alteraciones en la permeabilidad celular y expresión de un mecanismo de expulsión activa. Enferm Infecc Microbiol Clin 2004;22(4):200-7.
14. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluorquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1756-8.
15. Soriano F. Selección de bacterias resistentes a los antibióticos: factores microbiológicos y farmacológicos. Med Clin (Barc) 2001;117:632-6.
16. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9:38-44.
17. Craig WA. Pharmacokinetics and pharmacodinamics parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
18. Álvarez Lerma F, Palomar M, Olaechea P, León C, Sánchez M, Bermejo B, y Grupo de Estudio de Levofloxacino en UCI. Estudio observacinal sobre el uso de levofloxacino en pacientes ingresados en UCI. Enferm Infecc Microbiol Clin 2004;22(4):216-22.
19. Oteo J, Campos J, Baquero F, and the Spanish members of "European Antimicrobial Resistance Surveillance System." Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002;50:945-52.